Management of Brain Tumor Treatment with Tumor Morphometrics in Magnetic Resonanc

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43CA128188-01
Agency Tracking Number: CA128188
Amount: $200,619.00
Phase: Phase I
Program: SBIR
Awards Year: 2007
Solicitation Year: 2007
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
PRISM CLINICAL IMAGING, INC., 851 S. 70th St., Suite 103, West Allis, WI, 53214
DUNS: 190899638
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: Y
Principal Investigator
 JAMES REUSS
 (414) 727-1930
 jamesreuss@kyronclinical.com
Business Contact
 MICHAEL SCHMAINDA
Phone: (414) 727-1930
Email: michael@kyronclinical.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Radiology has traditionally relied upon qualitative assessment of tumor growth to guide therapeutic decision-making. The adoption of quantitative techniques such as WHO and RECIST guidelines in radiology has been slow due to multiple factors, including the workload and inter-operator variability associated with manual measurement, the complexity and pitfalls of automated techniques, and the many inherent sources of variability in medical imaging making longitudinal comparison difficult. We will develop, design and evaluate a semi- automated morphometrics system for quantification of tumors in the brain. The input to our system will be multiple images from magnetic resonance imaging (MRI) systems, particularly post-contrast T1 studies. The final product will be a modular extension to our FDA-cleared Prism View(tm) software package, compatible with MRI systems currently used for brain imaging. We will demonstrate feasibility in Phase I by developing means for geometrical registration and intensity standardization in imaging protocols, collecting data to document intra-patient and intra- and inter-reader variability, and evaluating our system in a study of a small number of subjects. In Phase II, we will further refine algorithms based upon Phase I findings and evaluate our system in a much larger cohort of subjects to more rigorously evaluate accuracy and precision in sizing of tumors. If successful, greater confidence will be achieved in following tumor changes over time, and this should translate into more rapid understanding of the efficacy of medical treatment or management of brain tumors. Our focus is on 2D and 3D tumor geometry, not on tumor composition. However, the existing product line (Prism) already facilitates combination and viewing of functional and physiologic information including MR spectroscopy and MR perfusion studies, and this information will be readily superposed upon the regions of interest delineated in anatomical imagery.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government